Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution

Archives of Internal Medicine

Volumn 158, Issue 17, 1998, Pages 1889-1893

  Bladé, Joan ^a   Fernández Llama, Patricia ^a   Bosch, Francesc ^a   Montolíu, Jesus ^a   Lens, Xosé M ^a,b   Montoto, Silvia ^a   Cases, Aleix ^a   Darnell, Alex ^a   Rozman, Ciril ^a   Montserrat, Emilio ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM; CARMUSTINE; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE SODIUM PHOSPHATE; DOXORUBICIN; FUROSEMIDE; GLUCOCORTICOID; MELPHALAN; PREDNISONE; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DIALYSIS; DRUG RESPONSE; FEMALE; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; KIDNEY FAILURE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032575885     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.17.1889     Document Type: Article

References (39)

1. DeFronzo RA, Humphrey RL, Wright JR, Cooke CR. Acute renal failure in multiple myeloma. Medicine (Baltimore). 1975;54:209-223.
2. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50:29-40.
3. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Intern Med. 1990;150:1693-1695.
4. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma. Eur J Haematol. 1994;53:207-212.
5. Bernstein SP, Humes HD. Reversible renal insufficiency in multiple myeloma. Arch Intern Med. 1982;142:2083-2086.
6. Cohen DJ, Sherman W, Osserman EF, Appel GB. Acute renal failure in patients with multiple myeloma. Am J Med. 1984;76:247-256.
7. Pozzi C, Pasquali S, Donini U, et al. Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma. Clin Nephrol. 1987;28:1-9.
8. Rota S, Mougenot B, Baudouin B, et al. Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine (Baltimore). 1987;66:126-137.
9. Torra R, Bladé J, Cases A, et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases Br J Haematol. 1995;91:854-859.
10. Chronic Leukemia-Myeloma Task Force, National Cancer Institute. Proposed guidelines for protocol studies, II. Cancer Chemother Rep. 1973;4:145-149.
11. Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302: 1347-1349.
12. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer. 1975;36:842-845.
13. Kaplan GL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
14. Peto R, Pike MC. Conservation of the approximation of (O-E)2/E in the log-rank test for survival data on tumour incidence rate. Biometrics. 1973;29:579-584.
15. Cox DR. Analysis of Binary Data. London, England: Methuen & Co Ltd; 1970.
16. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
17. Sanders PW. Pathogenesis and treatment of myeloma kidney. J Lab Clin Med. 1994;124:484-488.
18. Cavo M, Baccarani MM, Galieni P, Gobbi M, Tura S. Renal failure in multiple myeloma: a study of the presenting findings, response to treatment and prognosis in 26 patients. Nouv Rev Fr Hematol. 1986;28:147-152.
19. Misiani R, Tiraboschi G, Mingardi G, Mecca G. Management of myeloma kidney: an anti-light-chain approach. Am J Kidney Dis. 1987;10:28-33.
20. Medical Research Council Working Party on Leukemia in Adults. Analysis and management of renal failure in the fourth MRC myelomatosis trial. BMJ. 1984; 288:1411-1416.
21. Johnson WJ, Kyle RA, Dahlberg PJ. Dialysis in the treatment of multiple myeloma. Mayo Clin Proc. 1980;55:65-72.
22. Cosio FG, Pence TV, Shapiro FL, Kjellstrand CM. Severe renal failure in multiple myeloma. Clin Nephrol. 1981;15:206-210.
23. Lazarus HM, Adelstein DJ, Herzig RH, Smith MC. Long-term survival of patients with multiple myeloma and acute renal failure at presentation. Am J Kidney Dis. 1983;2:521-525.
24. Iggo N, Palmer ABD, Severn A, et al. Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment. QJM. 1989;270:903-910.
25. Coward RA, Mallick NP, Delamore IW. Should patients with renal failure associated with myeloma be dialysed? BMJ. 1983;287:1575-1578.
26. Pasquali S, Casanova S, Zucchelli A, Zucchelli P. Long-term survival in patients with acute and severe renal failure due to multiple myeloma. Clin Nephrol. 1990; 34:247-254.
27. Korzets A, Tam F, Russell G, Feenally J, Walls J. The role of continuous ambulatory peritoneal dialysis in end-stage renal failure due to multiple myeloma. Am J Kidney Dis. 1990;6:216-223.
28. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Arch Intern Med. 1990;150:863-869.
29. MacLennan ICM, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet. 1992;339:200-205.
30. Bladé J, San Miguel JF, Alcalá A, et al. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. J Clin Oncol. 1993;11:1165-1171.
31. Whalin A, Löfvenberg E, Holm J. Improved survival in multiple myeloma with renal failure. Acta Med Scand. 1987;221:205-209.
32. MacLennan ICM, Cooper EH, Chapman CE, Kelly KA, Crockson RA. Renal failure in myelomatosis. Eur J Haematol. 1989;43(suppl 51):60-65.
33. Boccadoro M, Pileri A. Standard chemotherapy for myelomatosis: an area of great controversy Hematol Oncol Clin North Am. 1992;6:371-382.
34. Aitchison RG, Reilly IAG, Morgan AG, Russell NH. Vincristine, Adriamycin and high dose steroids in myeloma complicated by renal failure. Br J Cancer. 1990;61:765-766.
35. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33:86-89.
36. Bergsagel DE. Chemotherapy of myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, eds. Myeloma: Biology and Management. Oxford. England: Oxford University Press; 1995:274-306.
37. Tricot G, Alberts DS, Johnson C, et al. Safety of autotransplantation with high-dose melphalan in renal failure. Clin Cancer Res. 1996;2:947-952.
38. Jagannath S, Barlogie B, Vesole D, Bracy D, Mattox S, Tricot G. Autotransplants can be performed safely in multiple myeloma patients with renal insufficiency [abstract]. Blood. 1995;86(suppl 1):205.
39. Bladé J, López-Guillermo A, Bosch F, et al. Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. Br J Haematol. 1994;88:117-121.